31. Cardiovascular risk stratification using SCORE2/SCORE2-OP charts and risk factors assessment among individuals undergoing health check-ups at T-Matsuoka clinic

Ho Thi Kim Thanh, Phung Gia Thanh

Main Article Content

Abstract

Cardiovascular risk stratification plays an essential role in clinical practice to guide the selection of appropriate strategies and preventive interventions. A cross-sectional descriptive study was conducted on 229 apparently healthy individuals who underwent health examinations at the T-Matsuoka Japanese Medical Clinic from June 2023 to April 2024. Data collection included anthropometric measurements, medical history, and laboratory test results. Cardiovascular risk was estimated and stratified using the SCORE2/SCORE2-OP models. The proportions of participants classified as having high and very high cardiovascular risk were 31.9% and 21.0%, respectively. Age-related distribution showed that very high risk was predominantly observed in the 50 - 69 and ≥ 70 age groups (23.6% and 94.7%, p < 0.001), while individuals < 50 years old were mainly categorized as low-to-moderate risk (73.5%). Male participants exhibited a significantly higher prevalence of very high cardiovascular risk compared with females (27% vs. 14%, p < 0.001). A history of hypertension, dyslipidemia, overweight/obesity, elevated blood glucose, and increased HbA1c were significantly associated with higher cardiovascular risk (p < 0.05). Individuals who appear clinically healthy may nonetheless present with high or very high cardiovascular risk, with a higher prevalence observed among men and older age groups (> 50 years old).

Article Details

References

1. World Health Organization. Cardiovascular diseases (CVDs). Published 2021. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases. Accessed August 6, 2025.
2. Martin SS, Aday AW, Allen NB, et al. 2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. Circulation. 2025; 151(8): e41-e660. doi:10.1161/CIR.0000000000001303.
3. SCORE2 Working Group and ESC Cardiovascular Risk Collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021; 42(25): 2439-2454. doi:10.1093/eurheartj/ehab309.
4. SCORE2-OP Working Group and ESC Cardiovascular Risk Collaboration. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur Heart J. 2021; 42(25): 2455-2467. doi:10.1093/eurheartj/ehab312.
5. Hageman SHJ, Huang Z, Lee H, et al. Risk Prediction of Cardiovascular Disease in the Asia Pacific Region: The SCORE2 Asia Pacific Model. ASEAN Heart J. 2024; 33(3): 1-14. doi:10.31762/AHJ2433.0301.
6. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34): 3227-3337.
7. Yusuf S, Joseph P, Dans A, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155,722 individuals from 21 countries (PURE study). Lancet. 2014; 384(9954): 766-781.
8. Choi J, Sung S, Park S, et al. SCORE and SCORE2 in East Asian Population: A Performance Comparison. JACC: Asia. 2024; 4(4): 265-274. doi:10.1016/j.jacasi.2023.10.013.
9. Đoàn Phạm Phước Long, Nguyễn Thị Thúy Hằng, Nguyễn Thị Lan Nhi, Nguyễn Thị Hương, Đoàn Phước Lộc, Hoàng Anh Tiến. Nghiên cứu nguy cơ tim mạch bằng thang điểm SCORE2 và SCORE2-OP ở người trưởng thành mắc tiền tăng huyết áp tại tỉnh Thừa Thiên Huế. Tạp chí Tim mạch học Việt Nam. 2024; (109): Tháng Năm. doi:10.58354/jvc.109.2024.847.
10. Hai TNP, Tai NN, Kha NM, et al. Reassessing Cardiovascular Risk Stratification in Vietnam: Insights from SCORE2 and the Original SCORE Model. Acta Inform Med. 2025; 33(2): 112-117. doi:10.5455/aim.2025.33.112-117.
11. Wilson PWF, D’Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998; 97(18): 1837-1847.
12. Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-pressure-related disease. Lancet. 2008; 371(9623): 1513-1518.